Speech Treatment for Minimally Verbal Children With ASD and CAS
NCT05066178
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Comorbid Childhood Apraxia of Speech (CAS) may be one factor that limits speech development in some minimally verbal children with autism. CAS is a disorder affecting speech movement planning. This study tests whether CAS-specific treatment, appropriately modified for minimally verbal children with autism, improves their speech.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Developmental Verbal Dyspraxia
- Autism Spectrum Disorder
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 5 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- MGH Institute of Health Professions
- Last updated on ClinicalTrials.gov
- March 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- MGH Institute of Health Professions · Boston, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.